European Research Council   Report issue

Government Phase 1 Phase 2 Phase 4
Founded: Brussels Belgium (2007)

Organization Overview

First Clinical Trial
2016
NCT02985437
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

European Research Council

Active Ingredients

Drugs in Phase 4 Trials (3)

fluticasone (cutivate) (1 trial)

ivermectin (stromectol) (1 trial)

salmeterol (serevent) (1 trial)

Drugs in Phase 2 Trials (1)

carboplatin (paraplatin) (1 trial)

Drugs in Phase 1 Trials (2)

sodium chloride (1 trial)

surfactant (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 4)

Connective Tissue Diseases (Phase 1)

Epilepsy (Phase 4)

Onchocerciasis (Phase 4)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6